Effects of FDA Advisories on the Pharmacologic Treatment of ADHD, 2004–2008
- 1 April 2013
- journal article
- research article
- Published by American Psychiatric Association Publishing in Psychiatric Services
- Vol. 64 (4) , 339-346
Abstract
ObjectiveThis study assessed the effect of public health advisories issued between 2005 and 2007 by the U.S. Food and Drug Administration (FDA) on treatments of attention-deficit hyperactivity disorder (ADHD) and physician prescribing practices.MethodsData obtained from the IMS Health National Disease and Therapeutic Index, a nationally representative audit of ambulatory physicians, were used to examine trends in office visits by children and adolescents (under age 18) during which ADHD was treated with Adderall, other psychostimulants, or atomoxetine. Segmented time series regressions were conducted to determine changes in use associated with three advisories issued between 2005 and 2007.ResultsIn 2004, before the first FDA advisory, Adderall accounted for 36% of ADHD pharmacotherapy treatment visits. Other stimulants accounted for 46%, and atomoxetine accounted for 19%. Overall pharmacotherapy treatment rates were stable over the study period, but by 2008 the treatment visits accounted for by Adderall (...Keywords
This publication has 35 references indexed in Scilit:
- Impact of FDA Drug Risk Communications on Health Care Utilization and Health BehaviorsMedical Care, 2012
- Trends in Attention Deficit Hyperactivity Disorder Ambulatory Diagnosis and Medical Treatment in the United States, 2000–2010Academic Pediatrics, 2012
- National Trends in Ambulatory Asthma Treatment, 1997–2009Journal of General Internal Medicine, 2011
- American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHDJournal of Developmental & Behavioral Pediatrics, 2008
- Cardiovascular Monitoring of Children and Adolescents With Heart Disease Receiving Medications for Attention Deficit/Hyperactivity DisorderCirculation, 2008
- Prevalence, Recognition, and Treatment of Attention-Deficit/Hyperactivity Disorder in a National Sample of US ChildrenArchives of Pediatrics & Adolescent Medicine, 2007
- Short- and Long-Term Cardiovascular Effects of Mixed Amphetamine Salts Extended Release in ChildrenThe Journal of Pediatrics, 2005
- The underutilization of cardiacmedications of proven benefit, 1990 to 2002JACC, 2003
- Cardiovascular Effects of Atomoxetine in Children, Adolescents, and AdultsDrug Safety, 2003
- Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled StudyAmerican Journal of Psychiatry, 2002